City
Epaper

Generics medicine industry unlikely to be impacted by Trump order: Indian Pharmaceutical Alliance

By ANI | Updated: May 13, 2025 14:27 IST

New Delhi [India], May 13 : India's generics medicine industry is unlikely to be impacted by President Donald Trump's ...

Open in App

New Delhi [India], May 13 : India's generics medicine industry is unlikely to be impacted by President Donald Trump's move to slash drug prices in the US drastically, said Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance (IPA).

On Monday, President Trump signed an Executive Order, which he termed as one of the "most consequential Executive Orders" in the country's history. The order directed pharmaceutical companies to lower the prices of their medicines to align with what other countries pay for such prescription medicines.

Trump gave pharmaceutical companies a 30-day deadline to cut costs or face action.

"The generics industry is unlikely to be impacted, as it operates on razor-thin margins. In the US, the generics industry represents 90 per cent of prescription volumes while accounting for only 13 per cent of the market value," Sudarshan Jain said.

The generics industry plays a pivotal role in ensuring medicines remain affordable and accessible.

"Further details on implementation mechanisms will bring more clarity," Jain added in his brief statement on Tuesday.

The Executive Order issued by the US Government seeks to balance innovation, access and overall healthcare costs.

"Research and development in life sciences demands long-term commitment, substantial investment, and carries high risk. The Order emphasises that the cost of the innovation should be shared equitably among all stakeholders," Jain said, arguing that the innovator companies are expected to be affected with a 30-day window to align their US prices with Most-Favoured-Nation (MFN) pricing.

Trump has been claiming that for many years, US consumers were paying much higher prices for medicines that are drastically lower in other countries.

The US President claimed that sometimes the medicines purchased by US consumers are five to ten times more expensive than the same drug, manufactured in the exact same laboratory or plant, and by the same company.

"Prescription Drug and Pharmaceutical prices will be REDUCED, almost immediately, by 30 per cent to 80 per cent. They will rise throughout the World in order to equalize and, for the first time in many years, bring FAIRNESS TO AMERICA! I will be instituting a MOST FAVORED NATION'S POLICY whereby the United States will pay the same price as the Nation that pays the lowest price anywhere in the World. Our Country will finally be treated fairly, and our citizens Healthcare Costs will be reduced by numbers never even thought of before. Additionally, on top of everything else, the United States will save TRILLIONS OF DOLLARS,"

Trump wrote on X, hours before signing the executive order.

President Trump has been focusing particularly on reducing Americans' cost of living ever since he stepped into the White House for the second time.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

Other Sports16-year-old Tanvi Sharma crowned world number one junior women's singles shuttler

NationalStampede incident: K'taka govt to challenge CAT order of quashing suspension of senior cop

National'Comments twisted by media': Bengal Minister after facing backlash over Kasba incident remarks

Cricket"Second spinner won't be bad option if...": Indian skipper Gill ahead of Birmingham Test

AurangabadRasta Roko demanding arrest of former MP in Waluj

Business Realted Stories

BusinessSEBI hosts municipal bond outreach programme in Thiruvananthapuram to boost urban financing

BusinessIndia's tax reforms, digital push have increased revenue, cut compliance costs: FM Sitharaman

BusinessMaha govt signs MoU for hydropower project and safari plaza, to generate 300 jobs

BusinessDES PU PG 2025 Phase 2 - Applications Closing Soon: July 20

BusinessGST collections rise 6.2 pc to touch Rs 1.85 lakh crore in June